// App-Quantinova.ai

2563 : Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin.

Researchers

Presenter

  • Siqing Fu

Principal Investigators

  • Eevy Nguyen

  • Filip Janku

  • Naiyi Shi

  • John S. Bomalaski

  • Patrick Hwu

  • Gerald Steven Falchook

  • Ralph Zinner

  • Apostolia Maria Tsimberidou

  • David S. Hong

  • Sarina Anne Piha-Paul

  • Jennifer J. Wheler

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Houston, TXPolaris Pharmaceuticals, San Diego, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Argininosuccinate Synthase 1

Drug/Treatment

  • Cisplatin

  • ADI-PEG20

Outcome

  • Positive

Study Design

  • pharmacodynamics

Phase

  • I

Study Id's

  • NCT01665183

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved